ADEL
Seoul
About ADEL
The company is a spin-off from Asan Medical Center, University of Ulsan University, with a primary objective of developing therapeutic and diagnostic agents for neurological diseases, particularly Alzheimer's disease. In 2016, the company took significant steps toward formalizing its presence in the market by completing its incorporation and business registration processes. The year 2017 proved to be a milestone for the company as it obtained certification as a corporate-affiliated research institute, solidifying its position as a reputable research-driven organization. Additionally, it garnered recognition as a leading university start-up by the Ministry of SMEs and Startups, further boosting its credibility and potential for growth. The company has collaborated with Oscotech Co., Ltd. and partnered with various investors, including Kite Entrepreneurship Foundation, Stone Bridge Ventures Co., Ltd., Korea Development Bank, and Stick Ventures Co., Ltd., to jointly develop their projects.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2024)
- Website: adelpharm.com
- Phone: +82 2-3010-4191
Industries & Categories
Health Care, Medical, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/adel-4424 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.